<DOC>
	<DOCNO>NCT01218737</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance 0.3 % gatifloxacin 1.0 % prednisolone acetate association eye drop prevention infection inflammation refractive surgery ( Lasik ) also demonstrate non-inferiority efficacy association compare administration 0.3 % gatifloxacin 1.0 % prednisolone acetate isolate eye drop formulation . The study treatment randomize , double-masked , 2 parallel arm . Each patient 's participation last 29 day , 15 day study treatment administration ocular surgery perform . Candidates study patient indication ocular refractive surgery ( Lasik ) correction visual acuity .</brief_summary>
	<brief_title>Non-Inferiority Gatifloxacin/Prednisolone Association vs Isolated Administration Prevention Ocular Infection/Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Eye Infections</mesh_term>
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patient indicate ocular refractive surgery perform ( myopia , astigmatism , hypermetropy ) Lasik method . Patient present normal eye fundus . Patient intraocular pressure ( IOP ) â‰¤ 20 mmHg . Surgery and/or previous ocular pathology ( presence scar/change cornea , glaucoma , retinopathy , etc. ) . Patient diabetes immunodepressed . Any systemic infection study . Signs and/or symptom ocular inflammation/infection ( bacterial , viral , fungal , caused Chlamydia , Mycobacterium , Acanthamoeba allergic etiology ) . Have use systemic topical antibiotic ocular infection previous 14 day . Patient known hypersensitivity component formulation use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>